High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection

Alimentary Pharmacology and Therapeutics

Volumn 47, Issue 9, 2018, Pages 1288-1295

  von Felden, J ^a   Vermehren, J ^a   Ingiliz, P ^a   Mauss, S ^a   Lutz, T ^a   Simon, K G ^a   Busch, H W ^a   Baumgarten, A ^a   Schewe, K ^a   Hueppe, D ^a   Boesecke, C ^a   Rockstroh, J K ^a   Daeumer, M ^a   Luebke, N ^a   Timm, J ^a   Schulze zur Wiesch, J ^a   Sarrazin, C ^a   Christensen, S ^a  

^a NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISPORIVIR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; ANTIVIRUS AGENT; CARBAMIC ACID DERIVATIVE; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; SOFOSBUVIR; VELPATASVIR; VIRAL PROTEIN;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENTION TO TREAT ANALYSIS; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEX RATIO; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECT; DRUG SUBSTITUTION; GENETICS; GENOTYPE; HEPACIVIRUS; PROCEDURES; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CARBAMATES; COHORT STUDIES; DRUG RESISTANCE, VIRAL; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; GERMANY; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS; YOUNG ADULT;

EID: 85043770569     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14592     Document Type: Article

References (32)

1. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017.
2. Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176.
3. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology. 2014;59:2403-2412.
4. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-2593.
5. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta-analysis. J Viral Hepat. 2011;18:745-759.
6. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636-1642.
7. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther. 2008;28:397-404.
8. Schulze Zur Wiesch J, Pudelski N, Hoepner L, et al. “Real-Life” comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus. Hepatology. 2011;53:1405-1406; author reply 7.
9. Berden FA, Aaldering BR, Groenewoud H, IntHout J, Kievit W, Drenth JP. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15:349-359.
10. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486-504.
11. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608-2617.
12. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-2607.
13. Hezode C, Reau N, Svarovskaia ES, et al. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 studies. J Hepatol. 2017; https://10.1016/j.jhep.2017.11.032. [Epub ahead of print].
14. European Medicines Agency: Epclusa - EMEA/H/C/004210 - II/0012 - EPAR - Product Information, 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004210/WC500211151.pdf. Nov 2017
15. Boesecke C, Ingiliz P, Berger F, et al. Liver cirrhosis as a risk factor for direct-acting antiviral therapy failure in real-life hepatitis C virus/human immunodeficiency virus coinfection. Open Forum Infect Dis. 2017;4:ofx158.
16. Ingiliz P, Christensen S, Kimhofer T, et al. Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV-coinfected individuals: results from the German hepatitis C cohort (GECCO-01). Clin Infect Dis. 2016;63:1320-1324.
17. Mauss S, Berger F, Wehmeyer MH, et al. Effect of antiviral therapy for HCV on lipid levels. Antivir Ther. 2017;21:81-88.
18. Wehmeyer MH, Ingiliz P, Christensen S, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol. 2018;90:304-312.
19. Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of Viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS ONE. 2015;10:e0134395.
20. Lawitz EJ, Dvory-Sobol H, Doehle BP, et al. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;60:5368-5378.
21. Feld JJ, Maan R, Zeuzem S, et al. Effectiveness and safety of sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis. 2016;63:776-783.
22. Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther. 2017;45:688-700.
23. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134-2146.
24. European Association for the Study of the Liver. Electronic address eee. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194.
25. Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017;66:1083-1089.
26. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
27. Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13-18.
28. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127-1135.
29. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932-954.
30. Dietz J, Susser S, Vermehren J, et al. Patterns of resistance-associated substitutions in patients with chronic hcv infection following treatment with direct-acting antivirals. Gastroenterology. 2017; https://10.1053/j.gastro.2017.11.007. [Epub ahead of print].
31. Soriano V, Labarga P, Fernandez-Montero JV, et al. Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opin Drug Metab Toxicol. 2017;13:807-816.
32. Mogalian E, Daryani V, Osinusi AO, et al. Pharmacokinetics of sofosbuvir/velpatasvir and tenofovir in subjects with HCV/HIV coinfection using boosted or unboosted antiretroviral regimens. Hepatology. 2016;64:419a-420a.